North America
Quanterix Q1 Revenues Fall 5 Percent
The company lowered its full-year 2025 revenue guidance, citing the impact of tariffs, cuts to academic funding, and lower biopharma spending.
Teal Health Wand Gets FDA Approval for At-Home HPV Self-Collection
The home-collected vaginal samples can be shipped to CLIA-certified labs for testing on the Roche Cobas system.
Top Five Articles on 360Dx Last Week: Castle Biosciences Buys Previse; Accelerate Dx's Bankruptcy; More
Last week, readers were most interested in a story about Castle Biosciences' buy of Previse and its plans to expand its gastrointestinal diagnostic test offerings.
New Grail Publication Explores Optimal Liquid Biopsy MCED Test Interval for Mortality Impact
Premium
Company investigators calculated the expected reduction in late-stage cancer diagnoses and projected drops in mortality for different screening schedules in different models of cancer growth.
Jefferies Upgrades GeneDx to Buy
Analysts at the investment bank are confident that GeneDx can achieve its promised 30 percent volume growth for WGS and WES tests in 2025, despite the underwhelming Q1 results.